Core Viewpoint - The Chinese biotech company, Insilico Medicine, has entered into an exclusive licensing and co-development agreement with Shenzhen Hengtai Biotechnology Co., Ltd. to accelerate the global development of its ISM8969 project, a novel NLRP3 inhibitor aimed at treating central nervous system diseases [1] Group 1: Partnership Details - Insilico Medicine and Shenzhen Hengtai will jointly advance the ISM8969 project, with both parties holding 50% global rights to the project [1] - The agreement allows Hengtai Biotechnology to conduct research, development, registration, production, and commercialization of ISM8969 worldwide [1] Group 2: Financial Aspects - Insilico Medicine is entitled to receive up to $66 million in upfront and milestone payments, including an initial payment of $10 million expected within 30 days of the agreement's effective date [1]
英矽智能称与衡泰生物达成超过5亿港元的全球战略合作